The Paragon Care Ltd. (ASX: PGC) share price shot to a more than three-month high on Monday after the healthcare equipment and services group announced the divestment of Axis Health, which is its Legacy Capital business, to Cabrini Health Limited.
The PGC share price jumped 9.6% to 46 cents as the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) and the All Ordinaries (Index:^AORD) (ASX:XAO) indices gained less than 0.5% each.
However, the stock has still lost nearly half of its value in FY19 even though other medical equipment stocks like the Azure Healthcare Ltd (ASX: AZV) share price, Nanosonics Ltd. (ASX: NAN) share price and RESMED/IDR UNRESTR (ASX: RMD) share price have made good gains over the past year.
Turning on an Axis
The Paragon share price should have also held up well amid the uncertain economic outlook but investors have been spooked by its restructure under new chief executive Andrew Just.
The company believes the sale of Axis Health marks a significant milestone in Paragon’s transformation programme, which aims to increase the group’s focus on “high end technologies and recurring revenues”.
While the divested business generated around $20 million in revenue, or 8% of group sales, it made a pre-tax loss of $4 million to $5 million in the last financial year. This will force management to take a circa $25 million write-down due primarily to goodwill, stock value reductions and IT impairments.
Cabrini, which is a highly recognised provider of hospital and age care facilities, will pay $1.8 million upfront in cash to Paragon and $2.7 million over the next 12 months. The buyer will also take responsibility for the 50 staff working at Axis Health and all properties used by the business.
A cleaner and leaner group
Paragon explained that the remaining businesses are less commoditised, less competitive and command higher margins. Management is also anticipating further significant savings from its cost reduction and efficiency initiatives that are currently under way.
“This is a clean sale of our legacy capital businesses to a well-respected buyer who is strategically focused in this sector to more efficiently manage this portfolio of businesses. We are pleased to now focus on our continuing portfolio of stronger margin products and services,” said Paragon’s chairman, Shane Tanner.
“The sale is consistent with our strategic direction and should prove to be a major positive for Paragon as we move into the 2019/20financial year”.
Paragon grew very quickly through an aggressive acquisition strategy and the refocusing of the group in more recent times introduces a different kind of execution risk.
Today’s asset divestment will help to alleviate some of the worry and the stock could be worth keeping an eye on.
If you are wondering where else you should be looking for opportunities, the experts at the Motley Fool can provide a few hints. They’ve produced a report on stocks that are well placed to outperform in FY20 and you can find out what these are by following the link below.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
Stock #1 is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Stock #2 is another high-growth business trading near a 52-week low all while offering a 4.7% grossed-up yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Paragon Care Limited and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.